Physician profile
Eric M Rettig
NPI 1053750547
$5,560.04
in general payments reported to CMS, 2019-2025
21 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $292 · 2021: $221 · 2022: $334 · 2023: $1,026 · 2024: $1,257 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,263 · Consulting Fee: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,263.24 |
| Consulting Fee | $550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,735.53 | 2019-2025 | Precision 1, Precision7, Total30 |
| Abbvie INC. | $588.40 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $421.86 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Coopervision INC. | $318.13 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Novartis Pharmaceuticals Corporation | $225.13 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $223.14 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $194.60 | 2019-2023 | Acuvue |
| Kala Pharmaceuticals, INC. | $133.70 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.18 | 2019-2021 | |
| Optovue, INC. | $108.99 | 2019 | |
| Oyster Point Pharma, INC. | $108.04 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $75.31 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $57.40 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $47.84 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $40.54 | 2024-2025 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $40.52 | 2023 | Tearcare System |
| Glaukos Corporation | $35.53 | 2025 | Idosetr |
| Lkc Technologies, INC. | $32.19 | 2025 | |
| Biotissue Holdings INC. | $29.62 | 2019-2025 | |
| Maculogix, INC. | $15.70 | 2019 | |
| Shire North American Group INC | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rettig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.